

## IN THE SPECIFICATION

Please replace page 13, line 12, with the following:

A<sub>1</sub> 1-(2-(6-Chloro-1H, indol-3-yl)ethyl-4-(1H-indol-4-yl)piperidine;

Please replace page 28, line 21, with the following:

A<sub>2</sub> C. Preparation of 5-fluorobenzofuran-3-yl acetic acid.

Please replace the fourth full paragraph, page 31, lines 15-20, with the following:

1d, 1-(4-(5-Fluoro-3-benzofuranyl)-1-butyl)-4-(1H-indol-4-yl)piperazine, dihydrochloride.

Mp 241-44°C, <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): 1.65-1.95 (m, 4H); 2.70 (t, 2H); 3.15-3.40 (m, 6H); 3.60 (d, 2H); 3.70 (d, 2H); 6.50 (s, 1H); 6.55 (d, 1H); 7.00 (t, 1H); 7.10 (d, 1H); 7.15 (dt, 1H); 7.30 (t, 1H); 7.45-7.60 (m, 2H); 7.90 (s, 1H); 10.95 (b, 1H); 11.20 (s, 1H). MS m/z (%): 392 (MH<sup>+</sup>, 90%), 234 (19%), 199 (23%), 163 (49%), 131 (11%).

## IN THE CLAIMS

Please cancel claims 7, 12, 15 and 16 without prejudice or disclaimer.

Please amend claims 1, 6, 11, 13, 14, 17 and 18 as follows.